Company Information

Location

London, UK

CEO

Jan-Anders Karlsson PhD

Website

www.veronapharma.com

Verona Pharma plc is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD and cystic fibrosis (CF). Verona Pharma’s lead drug, RPL554, is first-in-class. It offers a unique, dual mechanism of action unlike any other type of drug currently available or in development for respiratory diseases. Uniquely, it combines bronchodilator and anti-inflammatory properties in one compound and has the potential to benefit patients not satisfactorily treated with existing medicines.

RPL554 is currently being developed in a nebulized formulation for the maintenance treatment of COPD patients and as a treatment for CF. It is also being developed as an add-on therapy to commonly used therapies for the treatment of acute exacerbations of COPD in the hospital setting. It has the potential to substantially improve lung function and quality of life of patients not satisfactorily treated with existing drugs.

Additionally, Verona is also developing dry powder inhaler (DPI) and metered dose inhaler (MDI) formulations of RPL554 for maintenance treatment of COPD and may develop these formulations for asthma and other respiratory diseases.